Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE known ✓ | P22303 | 2/20 | 0.39 |
| ▸ | GAA known ✓ | P10253 | 2/20 | 0.34 |
| ▸ | CA2 known ✓ | P00918 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.33 |
| ▸ | PKM | P14618 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.33 |
| ▸ | RAB9A | P51151 | 4/20 | 0.33 |
| ▸ | TP53 | P04637 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.33 |
| ▸ | WNT3A | P56704 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL31150435 | 1.00 | TSHR (0.39) | TSHRACHETDP1CYP3A4TRPA1 | |
| Hydrochloric Acid SCHEMBL3327763 | 0.98 | TSHR (0.38) | TSHRACHETDP1CYP3A4TRPA1 | |
| SCHEMBL752673 | 0.98 | TSHR (0.41) | TSHRACHETDP1CYP3A4TRPA1 | |
| Water SCHEMBL5196978 | 0.95 | TSHR (0.39) | TSHRACHETDP1CYP3A4TRPA1 | |
| Hydrochloric Acid SCHEMBL4373437 | 0.91 | TSHR (0.39) | TSHRACHETDP1CYP3A4TRPA1 | |
| SCHEMBL753567 | 0.88 | TSHR (0.41) | TSHRACHETDP1CYP3A4TRPA1 | |
| Water SCHEMBL28584406 | 0.86 | TSHR (0.39) | TSHRACHETDP1CYP3A4TRPA1 | |
| Sulfuric Acid SCHEMBL2110043 | 0.86 | GAA (0.36) | TSHRACHETRPA1ATMGAA | |
| Acetic Acid SCHEMBL5196852 | 0.86 | GAA (0.40) | TDP1CYP3A4TRPA1GAAALDH1A1 | |
| Formic Acid SCHEMBL5197972 | 0.86 | ALDH1A1 (0.36) | TSHRACHETRPA1ATMGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 235 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260078142-A1 | FULLY-CONTINUOUS SYNTHESIS METHOD OF CYPROTERONE ACETATE | UNIV FUDAN (CN) | 2026-03-19 | — | — | US | claimed |
| CN-102596967-B | Prepare the photochemical method of Artemisinin | SAI NUOFEI (FR) | 2015-08-26 | — | — | CN | claimed |
| EP-2046767-B1 | PROCESS FOR PREPARING DIAMINOPHENOTHIAZINIUM COMPOUNDS | PROVENCE TECHNOLOGIES (FR) | 2015-04-22 | — | — | EP | claimed |
| US-8765942-B2 | Process for preparing diaminophenothiazinium compounds | PROVENCE TECHNOLOGIES (FR) | 2014-07-01 | — | — | US | claimed |
| US-20130299338-A1 | PHOTOCHEMICAL PROCESS FOR PRODUCING ARTEMISININ | SANOFI SA (FR) | 2013-11-14 | — | — | US | claimed |
| US-8507697-B2 | Photochemical process for producing artemisinin | SANOFI (FR) | 2013-08-13 | — | — | US | claimed |
| EP-2473512-A1 | PHOTOCHEMICAL PROCESS FOR PRODUCING ARTEMISININ | SANOFI (FR) | 2012-07-11 | — | — | EP | claimed |
| US-20110250296-A1 | REVERSE VITAMIN K EFFECT VIA PHOTODYNAMIC OXIDATION TARGETED AT VASCULAR ENDOTHELIUM, FIBRIN AND BLOOD PLATELETS | WINSLOW DAVID E | 2011-10-13 | — | — | US | claimed |
| US-7968127-B2 | Reverse vitamin K effect via photodynamic oxidation targeted at vascular endothelium, fibrin and blood platelets | WINSLOW DAVID E | 2011-06-28 | — | — | US | claimed |
| US-20100021566-A1 | REVERSE VITAMIN K EFFECT VIA PHOTODYNAMIC OXIDATION TARGETED AT VASCULAR ENDOTHELIUM, FIBRIN AND BLOOD PLATELETS | WINSLOW DAVID E | 2010-01-28 | — | — | US | claimed |
| US-20090291943-A1 | PROCESS FOR PREPARING DIAMINOPHENOTHIAZINIUM COMPOUNDS | PROVEPHARM LIFE SOLUTIONS (FR) | 2009-11-26 | — | — | US | claimed |
| EP-4017496-B1 | FORMULATIONS FOR USE IN THE PREVENTION AND/OR TREATMENT OF PERIPHERAL NEUROPATHY AND ITS ASSOCIATED DISEASES | LOH YIN SZE (SG) | 2026-01-07 | — | — | EP | disclosed |
| US-20250325557-A1 | 3, 7-DIAMINO-10H-PHENOTHIAZINE SALTS AND THEIR USE | WISTA LABORATORIES LTD. (SG) | 2025-10-23 | — | — | US | disclosed |
| US-20250222006-A1 | METHODS OF SYNTHESIS AND/OR PURIFICATION OF DIAMINOPHENOTHIAZINIUM COMPOUNDS | WISTA LABORATORIES LTD. (SG) | 2025-07-10 | — | — | US | disclosed |
| EP-3795565-B1 | IMPROVED PROCESS FOR THE PURIFICATION OF METHYLENE BLUE | RK PHARMA INC (US) | 2025-07-09 | — | — | EP | disclosed |
| US-6022549-A | NONAQUEOUS, COMPRISING A PHENOL ANTIMICROBIAL AGENT, A FILM FORMING RESIN, AND ORGANIC SOLVENT; THE PHENOL IS STORAGE STABLE AND CAPABLE OF LEACHING FOLLOWING SOLIDIFICATION OF THE NAIL COATING WITHOUT LOSING MICROBIOCIDAL ACTIVITY | WOODWARD LABORATORIES, INC. (US) | 2000-02-08 | — | — | US | disclosed |
| US-6013677-A | APPLYING TO THE NAIL A NON-AQUEOUS ANTIMICROBIAL NAIL COATING CONTAINING A FILM FORMING POLYMER, AN ORGANIC SOLVENT, A ANTIMICROBIAL AGENT COMPRISING SOLUBILZED BENZALKONIUM CHLORIDE AND CAPABLE OF LEACHING FROM NAIL COATING | WOODWARD LABORATORIES, INC. (US) | 2000-01-11 | — | — | US | disclosed |
| US-5968986-A | NONAQUEOUS NAIL COATING WITH MICROBIOCDES AND POLYMERS | WOODWARD LABORATORIES, INC. (US) | 1999-10-19 | — | — | US | disclosed |
| US-5961469-A | Spectrophotometric assay for cyanide | ROIZEN MICHAEL F (US) | 1999-10-05 | — | — | US | disclosed |
| WO-1999036033-A1 | ANTIMICROBIAL NAIL COATING COMPOSITION | WOODWARD LABORATORIES, INC. (US) | 1999-07-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250325557-A1 | 3, 7-DIAMINO-10H-PHENOTHIAZINE SALTS AND THEIR USE | PSEN1, PSEN2, APP | ACHE 1497/4885GAA 2333/4885CA2 2945/4885 |
| US-20250222006-A1 | METHODS OF SYNTHESIS AND/OR PURIFICATION OF DIAMINOPHENOTHIAZINIUM COMPOUNDS | MB, TPMT, HBB | ACHE 1987/4885GAA 734/4885CA2 3104/4885 |
| US-20100021566-A1 | REVERSE VITAMIN K EFFECT VIA PHOTODYNAMIC OXIDATION TARGETED AT VASCULAR ENDOTHELIUM, FIBRIN AND BLOOD PLATELETS | PROC, PFKP, TTPA | ACHE 4553/4885GAA 2858/4885CA2 2598/4885 |
| US-20110250296-A1 | REVERSE VITAMIN K EFFECT VIA PHOTODYNAMIC OXIDATION TARGETED AT VASCULAR ENDOTHELIUM, FIBRIN AND BLOOD PLATELETS | PROC, PFKP, TTPA | ACHE 4553/4885GAA 2858/4885CA2 2598/4885 |
| US-20130299338-A1 | PHOTOCHEMICAL PROCESS FOR PRODUCING ARTEMISININ | DHPS, FDPS, GGPS1 | ACHE 4123/4885GAA 1025/4885CA2 3783/4885 |
| US-20090291943-A1 | PROCESS FOR PREPARING DIAMINOPHENOTHIAZINIUM COMPOUNDS | DCPS, QDPR, DNPEP | ACHE 2384/4885GAA 380/4885CA2 2381/4885 |
| US-20260078142-A1 | FULLY-CONTINUOUS SYNTHESIS METHOD OF CYPROTERONE ACETATE | CYP17A1, CYP21A2, HSD17B2 | ACHE 823/4885GAA 1764/4885CA2 1121/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.